Paolo Nuciforo

List of Publications by Year in Descending Order

152 papers	7,628 citations	45 h-index	86 g-index
204 ext. papers	9,723 ext. citations	7.5 avg, IF	5.19 L-index

#	Paper	IF	Citations
152	Abstract P2-13-12: High CD36 expression predicts worse event free survival in HER2-positive breast cancer patients treated with neoadjuvant trastuzumab-based therapy: An exploratory analysis of the NeoALTTO study. *Cancer Research*, **2022**, 82, P2-13-12-P2-13-12	10.1	0
151	Abstract P1-07-02: Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC). *Cancer Research*, **2022**, 82, P1-07-02-P1-07-02	10.1	0
150	Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.. *Cancer Research*, **2022**, 82, 1646-1657	10.1	4
149	First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. *Frontiers in Oncology*, **2021**, 11, 744112	5.3	2
148	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. *Npj Breast Cancer*, **2021**, 7, 145	7.8	0
147	Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. *Npj Precision Oncology*, **2021**, 5, 23	9.8	5
146	Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. *Journal of the National Cancer Institute*, **2021**,	9.7	5
145	Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. *Nature Communications*, **2021**, 12, 1503	17.4	18
144	Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. *Journal of Clinical Investigation*, **2021**, 131,	15.9	26
143	PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. *British Journal of Cancer*, **2021**, 124, 1581-1591	8.7	4
142	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. *Radiology*, **2021**, 299, 109-119	20.5	14
141	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. *Npj Breast Cancer*, **2021**, 7, 73	7.8	2
140	Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. *Molecular Oncology*, **2021**, 15, 887-900	7.9	6
139	Tumor-Associated Microbiome: Where Do We Stand?. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	9
138	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. *Clinical Cancer Research*, **2021**, 27, 5607-5618	12.9	0
137	Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. *Clinical Cancer Research*, **2021**, 27, 6156-6163	12.9	1
136	High mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. *Clinical Cancer Research*, **2021**,	12.9	1

135	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. *Clinical Cancer Research*, **2021**, 27, 6307-6313	12.9	0
134	The Porto European Cancer Research Summit 2021. *Molecular Oncology*, **2021**, 15, 2507-2543	7.9	1
133	A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway. *Molecular Cancer Therapeutics*, **2021**, 20, 2250-2261	6.1	1
132	Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer. *British Journal of Cancer*, **2021**, 125, 1561-1569	8.7	0
131	Functional Mapping of AKT Signaling and Biomarkers of Response From the FAIRLANE Trial of Neoadjuvant Ipatasertib Plus Paclitaxel for Triple-Negative Breast Cancer.. *Clinical Cancer Research*, **2021**,	12.9	4
130	Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor. *Molecular Cancer Therapeutics*, **2020**, 19, 1289-1297	6.1	7
129	Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. *Annals of Oncology*, **2020**, 31, 1366-1375	10.3	31
128	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	12
127	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. *Nature Communications*, **2020**, 11, 385	17.4	36
126	The predictive role of plasma mutant allele fraction to antiangiogenic drugs in patients with mCRC: An expanded analysis of surrogate biomarkers of response to first-line treatment with bevacizumab.. *Journal of Clinical Oncology*, **2020**, 38, 3541-3541	2.2	
125	Association of T- and B-cell receptor repertoires with molecular subtypes and outcome in HER2+ breast cancer: An analysis of the NeoALTTO clinical trial.. *Journal of Clinical Oncology*, **2020**, 38, 511-511	2.2	
124	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. *Clinical Cancer Research*, **2020**, 26, 738-745	12.9	19
123	Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer. *Breast*, **2020**, 53, 102-110	3.6	2
122	Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype. *Science Translational Medicine*, **2020**, 12,	17.5	11
121	Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer. *European Journal of Radiology*, **2020**, 133, 109345	4.7	3
120	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. *Clinical Cancer Research*, **2020**, 26, 5820-5829	12.9	17
119	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. *Journal of the National Cancer Institute*, **2020**, 112, 46-54	9.7	48
118	Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. *Molecular Cancer Therapeutics*, **2020**, 19, 312-317	6.1	6

117	LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells. *Oncogene*, **2020**, 39, 79-121	9.2	10
116	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. *Clinical Cancer Research*, **2020**, 26, 3720-3731	12.9	10
115	Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. *Scientific Reports*, **2019**, 9, 13568	4.9	11
114	- and -Mutated Chemotherapy and Anti-EGFR-Refractory Colorectal Cancer: Should Clonality Guide Target Prioritization With Investigational Therapies?. *JCO Precision Oncology*, **2019**, 3, 1-3	3.6	1
113	Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. *Journal of Autoimmunity*, **2019**, 103, 102285	15.5	30
112	LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8 T cell tumor-infiltration impairing anti-PD1 therapy. *Nature Communications*, **2019**, 10, 2416	17.4	64
111	FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. *Annals of Oncology*, **2019**, 30, 1289-1297	10.3	55
110	A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. *Annals of Oncology*, **2019** , 30, 927-933	10.3	22
109	Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. *ESMO Open*, **2019**, 4, e000444	6	5
108	Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncology, The*, **2019**, 20, 1226-1238	21.7	55
107	PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors. *Annals of Oncology*, **2019**, 30, v760	10.3	2
106	Abstract PD3-03: SOLTI-1303 PATRICIA phase II trial (STAGE 1) -- Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer **2019**,		10
105	Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.. *Journal of Clinical Oncology*, **2019**, 37, 1050-1050	2.2	1
104	Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC).. *Journal of Clinical Oncology*, **2019**, 37, 1075-1075	2.2	2
103	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. *Journal of Clinical Oncology*, **2019**, 37, 571-571	2.2	4
102	On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.. *Journal of Clinical Oncology*, **2019**, 37, 574-574	2.2	4
101	Whole exome sequencing (WES) of non-small cell lung cancer (NSCLC) for tumor mutational burden (TMB) analysis and long-term benefit to immune checkpoint inhibitors (ICIs).. *Journal of Clinical Oncology*, **2019**, 37, 9071-9071	2.2	1
100	Analysis of Programmed Death-Ligand 1 Expression, Stromal Tumor-Infiltrating Lymphocytes, and Mismatch Repair Deficiency in Invasive Micropapillary Carcinoma of the Breast. *Journal of Immunotherapy and Precision Oncology*, **2019**, 2, 130-136	0.6	1

99	Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. *Oncologist*, **2019**, 24, 893-900	5.7	12
98	Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. *Journal of the National Cancer Institute*, **2018**, 110, 914-917	9.7	12
97	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. *Annals of Oncology*, **2018**, 29, 1203-1210	10.3	160
96	Early evolutionary divergence between papillary and anaplastic thyroid cancers. *Annals of Oncology*, **2018**, 29, 1454-1460	10.3	30
95	A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade. *Annals of Oncology*, **2018**, 29, 170-177	10.3	45
94	Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. *Journal of Experimental Medicine*, **2018**, 215, 1913-1928	16.6	21
93	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. *JAMA Oncology*, **2018**, 4, e181564	13.4	8
92	PAM50 intrinsic subtype in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial. *European Journal of Cancer*, **2018**, 92, S117-S118	7.5	3
91	Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial **2018**,		5
90	Abstract P5-20-19: PAM50 intrinsic subtype predicts survival outcome in HER2-positive/hormone receptor-positive metastatic breast cancer treated with palbociclib and trastuzumab: a correlative analysis of the PATRICIA (SOLTI 13-03) trial **2018**,		4
89	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. *Journal of Clinical Investigation*, **2018**, 128, 3887-3905	15.9	41
88	PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial.. *Journal of Clinical Oncology*, **2018**, 36, 1025-1025	2.2	2
87	First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.. *Journal of Clinical Oncology*, **2018**, 36, TPS2619-TPS2619	2.2	4
86	Real-world data on overall survival (OS) impact of anti-EGFR sequence in patients (pts) with microsatellite stable (MSS) all-RAS and BRAFV600E wild-type metastatic (met) colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2018**, 36, 3551-3551	2.2	
85	Translating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: Prevalence and outcome dataTranslating molecular subtypes of gastric and gastroesophageal junction cancer (GC and GEJC) to the metastatic (met) setting: prevalence and outcome data.. *Journal of Clinical Oncology*, **2018**, 36, 4071-4071	2.2	
84	Concordance of genomic alterations (GA) in synchronous tumor biopsies (tBx) and circulating tumor (ct) DNA from metastatic breast cancer (MBC) patients (pts).. *Journal of Clinical Oncology*, **2018**, 36, 1073-1073	2.2	
83	Immune profile and outcomes of patients (pts) with gynecological malignancies (GYN) enrolled in early phases immunotherapy (IO) trials.. *Journal of Clinical Oncology*, **2018**, 36, 5595-5595	2.2	1
82	Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy. *JCO Precision Oncology*, **2018**, 2018,	3.6	31

81	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. *Oncotarget*, **2018**, 9, 20617-20630	3.3	26
80	p95HER2-T cell bispecific antibody for breast cancer treatment. *Science Translational Medicine*, **2018**, 10,	17.5	40
79	A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. *EMBO Molecular Medicine*, **2018**, 10,	12	85
78	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. *Lancet Oncology, The*, **2017**, 18, 545-554	21.7	175
77	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. *Cancer Research*, **2017**, 77, 2213-2221	10.1	109
76	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. *Cancer Research*, **2017**, 77, 3540-3550	10.1	213
75	Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights. *Molecular Oncology*, **2017**, 11, 1263-1272	7.9	20
74	Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. *Annals of Oncology*, **2017**, 28, 1294-1301	10.3	107
73	Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). *Annals of Oncology*, **2017**, 28, 2451-2457	10.3	43
72	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma	5.1	299
71	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. *Advances in Anatomic Pathology*, **2017**, 24, 235-251	5.1	293
70	Analysis of persistence and antibiotic response in colorectal cancer. *Science*, **2017**, 358, 1443-1448	33.3	578
69	First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. *European Journal of Cancer*, **2017**, 81, 142-150	7.5	21
68	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. *Nature*, **2017**, 547, 109-113	50.4	92
67	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. *JAMA Oncology*, **2017**, 3, 227-234	13.4	79
66	Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. *Annals of Oncology*, **2017**, 28, 128-135	10.3	41
65	Abstract P1-09-09: Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer **2017**,		2
64	Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC). *Annals of Oncology*, **2017**, 28, v605	10.3	92

63	Impact of early trials in molecularly-characterized patients (pts) with head and neck cancer (HNC).. *Journal of Clinical Oncology*, **2017**, 35, 6031-6031	2.2	1
62	Impact of genomic heterogeneity on PI3K/AKT/mTOR inhibitors (PAMi) efficacy in gynecologic cancer (GYN) patients (pts).. *Journal of Clinical Oncology*, **2017**, 35, 5569-5569	2.2	1
61	Molecular markers to predict response to selective fibroblast growth factor receptor inhibitors (FGFRinh) in patients (pts) with FGFR-amplified (amp) or mutated (mut) tumors.. *Journal of Clinical Oncology*, **2017**, 35, 2581-2581	2.2	
60	Molecular sequencing and gene fusion detection in non-small cell lung cancer (NSCLC) patients: Impact of co-existing alterations.. *Journal of Clinical Oncology*, **2017**, 35, e23103-e23103	2.2	
59	RNAseq analysis of the sorafenib phase III DECISION trial in differentiated thyroid cancer (DTC): Correlation with clinical outcome.. *Journal of Clinical Oncology*, **2017**, 35, 6083-6083	2.2	1
58	Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. *Clinical Cancer Research*, **2016**, 22, 560-6	12.9	57
57	Tankyrase Inhibition Blocks Wnt/Β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. *Clinical Cancer Research*, **2016**, 22, 644-56	12.9	114
56	Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. *JAMA Oncology*, **2016**, 2, 1287-1294	13.4	65
55	High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. *Molecular Oncology*, **2016**, 10, 138-147	7.9	52
54	Matching degree between PI3K/AKT/mTOR (PAM) pathway mutations (mut) and therapy (ttx) as predictor of clinical benefit (ClinBen) in early trials.. *Journal of Clinical Oncology*, **2016**, 34, 2572-2572	2.2	2
53	Patient-derived AVATAR mouse models to predict prognosis in advanced renal cell carcinoma.. *Journal of Clinical Oncology*, **2016**, 34, 551-551	2.2	2
52	Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. *Oncotarget*, **2016**, 7, 56295-56308	3.3	38
51	Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in patients (pts) with metastatic breast cancer (MBC).. *Journal of Clinical Oncology*, **2016**, 34, 528-528	2.2	2
50	Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. *Annals of Oncology*, **2015**, 26, 1280-91	10.3	127
49	Quantification of HER family receptors in breast cancer. *Breast Cancer Research*, **2015**, 17, 53	8.3	30
48	Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. *Annals of Oncology*, **2015**, 26, 1494-500	10.3	34
47	MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. *Clinical Cancer Research*, **2015**, 21, 5499-5510	12.9	13
46	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. *JAMA Oncology*, **2015**, 1, 448-54	13.4	359

45	Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. *Cancer Cell*, **2015**, 28, 170-82	24.3	99
44	High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. *Clinical Cancer Research*, **2015**, 21, 569-76	12.9	58
43	PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. *Clinical Cancer Research*, **2015**, 21, 2065-74	12.9	47
42	PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. *Journal of Clinical Oncology*, **2015**, 33, 1334-9	2.2	164
41	Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic. *Cellular Oncology (Dordrecht)*, **2015**, 38, 39-48	7.2	7
40	Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies. *PLoS ONE*, **2015**, 10, e0129876	3.7	28
39	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. *Oncotarget*, **2015**, 6, 37269-80	3.3	112
38	Clinical and molecular characterization of refractory BRAF mutant metastatic colorectal carcinoma (mCRC): Vall dHebron Institute of Oncology phase I program cohort.. *Journal of Clinical Oncology*, **2015**, 33, 587-587	2.2	
37	Measuring the impact of Next Generation Sequencing (NGS) technique implementation in metastatic colorectal cancer (mCRC) drug development program.. *Journal of Clinical Oncology*, **2015**, 33, 3598-3598	2.2	
36	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. *Annals of Oncology*, **2014**, 25, 1729-1735	10.3	258
35	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing. *Molecular Oncology*, **2014**, 8, 150-8	7.9	34
34	Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. *Annals of Oncology*, **2014**, 25, 552-563	10.3	242
33	The Fragile X Protein binds mRNA s involved in cancer progression and modulates metastasis formation. *EMBO Molecular Medicine*, **2014**, 6, 567-568	12	78
32	Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	30
31	Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy.. *Journal of Clinical Oncology*, **2014**, 32, 649-649	2.2	1
30	Coexisting KRAS and PIK3CA exon 20 mutations as a potential poor-prognosis factor in metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2014**, 32, 3591-3591	2.2	
29	Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies. *Regulatory Peptides*, **2013**, 187, 35-41		12
28	Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system. *Journal of Clinical Pathology*, **2013**, 66, 124-35	3.9	37

27	Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. *Cancer Discovery*, **2013**, 3, 1238-44	24.4	38
26	The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation. *EMBO Molecular Medicine*, **2013**, 5, 1523-36	12	78
25	Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. *Scientific Reports*, **2013**, 3, 3544	4.9	42
24	Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors. *Neuroendocrinology*, **2012**, 95, 232-47	5.6	26
23	Pirin inhibits cellular senescence in melanocytic cells. *American Journal of Pathology*, **2011**, 178, 2397-406	5.8	25
22	A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. *Pigment Cell and Melanoma Research*, **2011**, 24, 326-33	4.5	56
21	An atlas of altered expression of deubiquitinating enzymes in human cancer. *PLoS ONE*, **2011**, 6, e15891	3.7	78
20	Prep1 (pKnox1)-deficiency leads to spontaneous tumor development in mice and accelerates EmuMyc lymphomagenesis: a tumor suppressor role for Prep1. *Molecular Oncology*, **2010**, 4, 126-34	7.9	32
19	DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2010**, 33, 341-5	2.7	31
18	Chromosomal rearrangements in acute myeloid leukemia (AML). *Ecancermedicalscience*, **2010**, 4, 183	2.7	
17	The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer. *Nature Cell Biology*, **2009**, 11, 133-42	23.4	139
16	Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor. *Oncogene*, **2009**, 28, 2959-68	9.2	75
15	NUMB controls p53 tumour suppressor activity. *Nature*, **2008**, 451, 76-80	50.4	298
14	Breast cancer metastases are molecularly distinct from their primary tumors. *Oncogene*, **2008**, 27, 2148-58	9.2	97
13	Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. *Cancer Research*, **2008**, 68, 7788-94	10.1	138
12	Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimurium immunity. *Journal of Experimental Medicine*, **2008**, 205, 657-67	16.6	20
11	Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. *Annals of Oncology*, **2008**, 19, 1875-81	10.3	39
10	Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of antiSalmonella typhimuriumimmunity. *Journal of Cell Biology*, **2008**, 180, i17-i17	7.3	

9	Gene expression analysis of early and advanced gastric cancers. *Oncogene*, **2007**, 26, 4284-94	9.2	60
8	Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. *Nature*, **2007**, 448, 1063-7	50.4	249
7	Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. *Journal of Clinical Investigation*, **2007**, 117, 3436-44	15.9	94
6	Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. *Genes and Development*, **2006**, 20, 3426-39	12.6	403
5	8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. *Genes Chromosomes and Cancer*, **2005**, 42, 320-5	5	89
4	Malakoplakia of the pancreas with diffuse lymph-node involvement. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2003**, 442, 82-5	5.1	8
3	CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2003**, 443, 782-6	5.1	65
2	Lymphomas of the bone: a pathological and clinical study of 54 cases. *International Journal of Surgical Pathology*, **2002**, 10, 257-66	1.2	36
1	Inflammatory pseudo bladder tumour: Clinical case. *Urologia*, **1997**, 64, 430-433	1.2	